Other
Laryngopharyngeal Reflux
12
Pipeline Programs↗
1
Active Trials↗
8
Companies Involved↗
Laryngopharyngeal Reflux is an emerging landscape with 12 programs across 8 companies. The most active players are Teva, Shandong Luoxin Pharmaceutical Group Stock Co., Ltd., Dong-A Pharmaceutical Co., Ltd.. 5 therapies are approved with 4 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical1
Phase 11
Phase 34
Analysis
Trial Status
11
clinical trials
Completed7 · 64%
Unknown status2 · 18%
Withdrawn1 · 9%
Recruiting1 · 9%
Clinical Trials
Trial Activity
11 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)